CClinicalTrials.gg
RecruitingNCT07453069Updated Sep 3, 2026

Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer Cycle

A Phase 2 interventional study of FB-301 and Placebo in Vaginal Dysbiosis, sponsored by Freya Biosciences ApS. Recruiting at 4 sites in United States. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Freya Biosciences ApS · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The goal of this clinical trial is to evaluate FB301 during a mock frozen embryo transfer (FET) cycle in pre-menopausal women aged 18 to 40 years with a prior failed FET and a defined vaginal bacterial imbalance (dysbiosis).

The main question it aims to answer is:

  • Does treatment with FB301 during a mock FET cycle change the proportion of participants who meet the predefined vaginal bacterial threshold compared with placebo?

Researchers will compare:

  • FB301 given after an initial vaginal cleansing with chlorhexidine (an antiseptic solution),
  • FB301 given after an initial vaginal cleansing with saline (saltwater), and
  • A placebo capsule given after an initial vaginal cleansing with saline to determine whether these approaches affect vaginal bacterial composition and pregnancy outcomes.

Participants will take study treatment for 15 days during a "mock" FET cycle. In a mock cycle, participants receive the hormones needed to prepare the uterus for embryo transfer, but no embryo is transferred. After completing the mock cycle, participants will proceed with their planned frozen embryo transfer and will be followed during pregnancy until birth.

Participants will:

  • Undergo a vaginal cleansing before receiving the first dose of FB301 or placebo
  • Provide vaginal swab samples at up to 5 study visits
  • Attend the study centre for up to 8 visits and participate in up to 4 follow-up phone calls
  • Complete a mock FET cycle before proceeding with their planned frozen embryo transfer cycle

Participants who become pregnant will be followed until birth.

Read the detailed description

Vaginal dysbiosis characterized by reduced relative abundance of Lactobacillus species has been associated with reproductive outcomes in women undergoing frozen embryo transfer (FET). This study evaluates the safety, tolerability, and molecular effects of FB301 in women undergoing FET who have no known underlying clinical gynecological conditions but are identified as having molecular dysbiosis by metagenomic sequencing of a vaginal swab collected at screening.

Participants will be randomized to one of three arms: (1) FB301 following a single initial vaginal cleansing with chlorhexidine (an antiseptic solution), (2) FB301 following a single sham cleansing with saline, or (3) placebo following sham cleansing. Cleansing occurs once prior to initiation of study treatment. Participants will then receive 15 days of study treatment during a mock frozen embryo transfer (FET) cycle in which participants receive hormonal preparation of the endometrium but no embryo is transferred. Following completion of the mock cycle, participants will proceed with their planned frozen embryo transfer during the subsequent menstrual cycle, in accordance with standard clinical practice. Participants who become pregnant will be followed until birth.

The primary objective is to evaluate whether treatment increases the proportion of participants achieving a predefined Lactobacillus-dominant vaginal bacterial profile following therapy. Secondary objectives include evaluation of biochemical pregnancy (confirmed by serum beta-hCG testing) and clinical pregnancy (confirmed by transvaginal ultrasound) following the subsequent planned FET cycle.

02

Conditions studied

  • Vaginal Dysbiosis
03

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. Able to understand the study and sign a consent form.
  2. Is a woman aged 18 to 40 years.
  3. Still has regular menstrual periods (pre-menopausal).
  4. Has had at least one previous frozen embryo transfer (FET) that did not result in pregnancy within the past 3 years, and this was not due to either male infertility or blocked /damaged fallopian tubes.
  5. Planning to have a frozen embryo transfer (FET) using one good-quality embryo (grade 3BB or higher) and are considered medically suitable to proceed.
  6. Willing to have only one embryo transferred during the study cycle.
  7. A vaginal swab taken at the first study visit shows a specific vaginal microbiome imbalance required for this study (vaginal molecular dysbiosis).
  8. An ultrasound scan shows no problems with uterus or pelvis that would prevent pregnancy or greatly reduce the chance of pregnancy.
  9. Recent fertility blood tests (within the last 6 months) show:

    • FSH less than 12 IU/L
    • AMH greater than 1 ng/mL
  10. Body mass index (BMI) is between 18 and 38 kg/m².
  11. From the first study treatment until the mock FET cycle, agrees to:

    • Avoid vaginal intercourse or use condoms (without spermicide or lubricant),
    • Avoid swimming or hot tubs,
    • Avoid using tampons, menstrual cups, sex toys, vaginal cleansers, lubricants, or other vaginal products unless approved by the study team.
  12. Willing to answer questions about sexual and reproductive activity during the study.
  13. Willing to provide vaginal swab samples at the clinic.
  14. Willing to receive the first study treatment in the clinic and use the study treatment at home as instructed.
  15. Screening blood tests are negative for hepatitis B, hepatitis C, HIV, and syphilis.
  16. Willing to attend all study visits and follow-up assessments and provide information about pregnancy and newborn health outcomes.

Exclusion criteria

Exclusion Criteria:

  1. History of three or more failed frozen embryo transfers (FET) in the past 3 years.
  2. Have a condition that weakens the immune system (such as uncontrolled diabetes, active cancer, or an organ transplant).
  3. Currently taking medications that suppress the immune system (such as systemic steroids, biologics, chemotherapy, or transplant medications).
  4. Is already pregnant before completing the mock FET cycle.
  5. Test positive for a sexually transmitted infection (such as chlamydia, gonorrhea, Mycoplasma genitalium, or Trichomonas vaginalis).
  6. Current vaginal yeast infection that requires treatment.
  7. YCannot safely take the hormone medications required for a frozen embryo transfer (such as estradiol or progesterone).
  8. Use of intravaginal progesterone gels or solutions.
  9. Needs regular antibiotics or are likely to require antibiotics during the study.
  10. Has taken oral, injectable, or vaginal antibiotics within 30 days before screening.
  11. History of gynecological cancer or other significant gynecological condition that would make participation unsafe.
  12. Has a medical condition that would make participation unsafe or difficult.
  13. Has an unstable medical or psychiatric condition that could make it difficult to follow study requirements.
  14. Has any other condition that could interfere with participation.
04

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    FB301 / Chlorhexidine

    Drug: FB-301 · Other: Chlorhexidine (0.5%) Vaginal Cleanse

  • Experimental
    FB301 / Sham

    Drug: FB-301 · Other: Sham vaginal cleanse (saline)

  • Placebo comparator
    Placebo / Sham

    Drug: Placebo · Other: Sham vaginal cleanse (saline)

Interventions

  • DrugFB-301

    FB301 capsule

  • DrugPlacebo

    FB301 Placebo capsule

  • OtherChlorhexidine (0.5%) Vaginal Cleanse

    Vaginal cleanse with 0.5% Chlorhexidine solution prior to first IP administration

  • OtherSham vaginal cleanse (saline)

    Vaginal cleanse with saline solution prior to first IP administration.

05

What researchers measure

Primary outcomes

  1. Proportion of participants with ≥90% combined relative abundance of Lactobacillus crispatus, L. jensenii, L. mulieris, L. gasseri, and L. paragasseri as measured by metagenomic sequencing.

    Metagenomic sequencing is performed on cervical vaginal swab samples. Relative abundance is expressed as a percentage of bacterial sequencing reads that are assigned to a specific bacterial species.

    Time frame: Baseline to Day 16 (Mock FET cycle)

Secondary outcomes

  1. Percentage change from baseline in relative abundance of Lactobacillus crispatus, L. jensenii, L. mulieris, L. gasseri, and L. paragasseri as measured by metagenomic sequencing.

    Metagenomic sequencing is performed on cervical vaginal swab samples. Relative abundance is expressed as a percentage of bacterial sequencing reads that are assigned to a specific bacterial species.

    Time frame: Baseline to Day 16 (Mock FET cycle)

  2. Biochemical pregnancy rate following frozen embryo transfer (FET), defined as a positive serum beta-human chorionic gonadotropin (hCG) test.

    Time frame: 12-14 days after frozen embryo transfer (FET)

  3. Clinical pregnancy rate following frozen embryo transfer (FET), defined as the presence of a fetal heartbeat confirmed by transvaginal ultrasound.

    Time frame: 5-6 weeks after frozen embryo transfer (FET)

  4. Frequency and intensity of all treatment-emergent adverse events (TEAEs), adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest) AESI

    Time frame: Baseline to End of Study (up to neonatal follow-up assessment (Visit 11), approximately 10 months after FET)

  5. The incidence of early pregnancy loss, defined as a positive beta-hCG test (biochemical pregnancy) at 12-14 days after FET but no transvaginal ultrasound-confirmed fetal heartbeat at 5-6 weeks after FET (Visit 7)

    Time frame: 5-6 weeks after FET

06

Study locations

2 of 4 sites recruiting
  • Cypress Medical Research Centre
    Wichita, Kansas 67226, United States
    Recruiting
  • Boston IVF
    Waltham, Massachusetts 02451, United States
    • Kristin Rooney · Contact · krooney@bostonivf.com · 781-434-6470
    • Nina Resetkova, MD, MBA · Principal investigator
    Not yet recruiting
  • REACH Fertility
    Charlotte, North Carolina 28207, United States
    Not yet recruiting
  • Delta Hy Research LLC / Advanced Fertility Texas
    Houston, Texas 77079, United States
    Recruiting
07

References and documents

Individual participant data

Plan to share: No — There are no current plans to share individual participant data.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07453069
Lead sponsor
Freya Biosciences ApS
Collaborators
Premier Research
Responsible party
Sponsor
First posted
Mar 5, 2026
Start date
Jul 22, 2026
Primary completion
Oct 31, 2026 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Sep 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion